

# Cambridge Pharmaceuticals Limited

## REPORT AND FINANCIAL STATEMENTS

for the year ended  
31 March 2012



# Cambridge Pharmaceuticals Limited

## DIRECTORS AND OFFICERS

---

### DIRECTORS

M Avedissian  
BL Eghayan  
DM Hicks  
K Sarkissian

### SECRETARY

BL Eghayan

### REGISTERED OFFICE

23 Wigmore Street  
London W1U 1PL

# Cambridge Pharmaceuticals Limited

## DIRECTORS' REPORT

---

The directors submit their report and the financial statements of Cambridge Pharmaceuticals Limited for the year ended 31 March 2012

### PRINCIPAL ACTIVITIES

The company was dormant throughout the period

### REVIEW OF THE BUSINESS

The company remained dormant throughout the period


### DIRECTORS

The following directors have held office since 1 April 2009

M Avedissian  
BL Eghayan  
DM Hicks  
K Sarkissian

This report has been prepared in accordance with the special provisions of the Companies Act 2006 relating to small companies

On behalf of the board



B L Eghayan  
Director

# Cambridge Pharmaceuticals Limited

## DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

---

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to

- a select suitable accounting policies and then apply them consistently,
- b make judgements and estimates that are reasonable and prudent,
- c prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the requirements of the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# Cambridge Pharmaceuticals Limited

## BALANCE SHEET

31 March 2012

	<i>Notes</i>	2012 £	2011 £
<b>CURRENT ASSETS</b>			
Debtors	3	100	100
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>100</u>	<u>100</u>
<b>CAPITAL AND RESERVES</b>			
Called up share capital	4	100	100
<b>SHAREHOLDERS' FUNDS</b>		<u>100</u>	<u>100</u>


For the period ended 31 March 2012 the company was entitled to exemption from audit under section 480 of the Companies Act 2006

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006

The directors acknowledge their responsibility for

- a Complying with the requirements of the Act with respect to accounting records and for the preparation of accounts

Approved by the board and authorised for issue on

  
B L Eghriayan  
Director

# Cambridge Pharmaceuticals Limited

## NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 March 2012

---

### 1 BASIS OF ACCOUNTING

The accounts have been prepared under the historical cost convention

### 2 DEBTORS

	2012 £	2011 £
--	-----------	-----------

Due within one year

Other debtors

100

100

### 3 SHARE CAPITAL

	2012 £	2011 £
--	-----------	-----------

Authorised

100 ordinary shares of £1 each

100

100

Allotted, issued and fully paid

100 ordinary shares of £1 each

100

100

### 4 RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' FUNDS

	2012 £	2011 £
--	-----------	-----------

Result for the financial period

-

-

Net addition to shareholders' funds

-

-

Opening shareholders' funds

100

100

Closing shareholders' funds

100

100